Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Study ID: NCT00405405
Phase: PHASE1
Status: Completed

Conditions

Head and Neck Cancer
Melanoma
Parotid Gland Cancer
Stage IV Head and Neck Cancer
Thyroid Gland Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Cisplatin — DRUG
* Two cycles during neoadjuvant therapy * Response assessment at approximately day 36 * Concurrent biochemoradiotherapy
Docetaxel — DRUG
* Two cycles during neoadjuvant therapy * Response assessment at approximately day 36 * Concurrent biochemoradiotherapy
Bevacizumab — DRUG
* Two cycles during neoadjuvant therapy * Response assessment at approximately day 36 * Concurrent biochemoradiotherapy
Erlotinib — DRUG
* Two cycles during neoadjuvant therapy (dose escalation) * Response assessment at approximately day 36 * Concurrent biochemoradiotherapy
Radiotherapy — RADIATION
Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks

Study Details

To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer